"Cold" tumor becomes "hot" Oncolytic virus/CAR-T combination therapy Phase 1 clinical trial is about to start

Recently, Mustang Bio, a company specializing in the development of cell and gene therapy (hereinafter referred to as Mustang), announced plans to initiate a combination of MB-101 (CAR-T cell therapy targeting IL13Rα2) and MB-108 (C134 oncolytic virus) in the treatment of recurrent Phase 1 clinical trial in glioblastoma (rGBM)

rGBM is one of the most common and malignant primary intracranial tumors in adults, characterized by high morbidity, high recurrence, high mortality and low cure rate

MB-101 is a CAR-T cell therapy targeting IL13Rα2, a receptor restricted to GBM and abundantly expressed in most GBM tumors

MB-108 is a second-generation attenuated herpes simplex virus type 1 (HSV-1) oncolytic virus that improves replication in tumors in mouse models compared to the first generation, but has a similar toxicity profile to the first generation

MB-109 is a treatment regimen for the combination of the above two drugs

A phase 1 clinical trial evaluating MB-101 was conducted in 65 patients with heavily pretreated relapsed or refractory malignant glioma

The clinical trial evaluating MB-108 included 24 patients with recurrent malignant glioma

Dr.

References:

1.